Lisuride as an alternative to bromocryptine in treatment of hyperprolactinemic, galactorrheic and non-galactorrheic patients

ABSTRACT

The results of this study offer a reasonable evidence that dopergin [lisuride] is a valuable altermative to bromocryptine in the suppression of excessive prolactin secretion and management of hyperprolactinemic menstrual cycle and fertility disorders. Sixty-two hyperprolactinemic women including 14 amenorrheic galactorrheic, 30 infertile galactorrheic and 18 infertile but non-galactorrheic took part in a double blind trial to compare the efficiency of dopergin 0.6 mg/day and bromocryptine 7.5 mg/day in suppression of serum prolaction [PRL], breast activity and restoration of the menstrual function. A better clinical response to the action of dopergin on mammary secretory activity has been demonstrated. The incidence of partial or failed response to dopergin was 9.8% for the bromocryptine group. Also restoration of normal menstrual function was reported in 71.4% and 91.68% of patients receiving dopergin compared to an incidence of 64.24% and 85.68% of the bormocryptine group at 12 and 24 weeks respectively. Serum PRL level was not statistically significantly different between groups by the end of therapy. An increased incidence of side effects was reported for the bromocryptine group